Advertisement
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

References

  • 1 Jacks T, Jaffee E and Singer D: Cancer Moonshot Blue Ribbon Panel Report 2016. Available at https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel/blue-ribbon-panel-report-2016.pdf. Google Scholar
  • 2 : AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med2014; 371: 1028. Google Scholar
  • 3 : Prostate cancer: AR splice variant dimerization-clinical implications. Nat Rev Urol2015; 12: 431. Google Scholar
  • 4 : AR-V7 transcripts in whole blood RNA of patients with metastatic castration resistant prostate cancer correlate with response to abiraterone acetate. J Urol2017; 197: 135. LinkGoogle Scholar
  • 5 : Molecular analysis of low grade prostate cancer using a genomic classifier of metastatic potential. J Urol2017; 197: 122. LinkGoogle Scholar
  • 6 : Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series. Urol Oncol2011; 29: 508. Google Scholar
  • 7 : A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol2014; 66: 550. Google Scholar
  • 8 : Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer2015; 113: 382. Google Scholar
  • 9 : Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer2012; 118: 3512. Google Scholar
Advertisement